These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22658485)

  • 1. 'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors.
    Rikhof B; van der Graaf WT; Suurmeijer AJ; van Doorn J; Meersma GJ; Groenen PJ; Schuuring EM; Meijer C; de Jong S
    Am J Pathol; 2012 Jul; 181(1):303-12. PubMed ID: 22658485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
    Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A
    Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells.
    Vitale G; van Koetsveld PM; de Herder WW; van der Wansem K; Janssen JA; Colao A; Lombardi G; Lamberts SW; Hofland LJ
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E559-66. PubMed ID: 19141687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.
    Avnet S; Sciacca L; Salerno M; Gancitano G; Cassarino MF; Longhi A; Zakikhani M; Carboni JM; Gottardis M; Giunti A; Pollak M; Vigneri R; Baldini N
    Cancer Res; 2009 Mar; 69(6):2443-52. PubMed ID: 19258511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A.
    Sciacca L; Mineo R; Pandini G; Murabito A; Vigneri R; Belfiore A
    Oncogene; 2002 Nov; 21(54):8240-50. PubMed ID: 12447687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
    Nussbaum T; Samarin J; Ehemann V; Bissinger M; Ryschich E; Khamidjanov A; Yu X; Gretz N; Schirmacher P; Breuhahn K
    Hepatology; 2008 Jul; 48(1):146-56. PubMed ID: 18537183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine stimulation by insulin-like growth factor 1 and insulin-like growth factor 2 mediates chondrocyte survival in vitro.
    Loeser RF; Shanker G
    Arthritis Rheum; 2000 Jul; 43(7):1552-9. PubMed ID: 10902760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
    Reeve JG; Morgan J; Schwander J; Bleehen NM
    Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
    Bauer S; Yu LK; Demetri GD; Fletcher JA
    Cancer Res; 2006 Sep; 66(18):9153-61. PubMed ID: 16982758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions.
    Guo YS; Jin GF; Townsend CM; Zhang T; Sheng HM; Beauchamp RD; Thompson JC
    J Am Coll Surg; 1995 Aug; 181(2):145-54. PubMed ID: 7627387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases.
    Tariq Z; Ghose A; Rafiq E; Mohamed I
    Am J Ther; 2011 Sep; 18(5):e188-90. PubMed ID: 20535017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.
    El-Badry OM; Minniti C; Kohn EC; Houghton PJ; Daughaday WH; Helman LJ
    Cell Growth Differ; 1990 Jul; 1(7):325-31. PubMed ID: 2177632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
    Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
    Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.